A blinded, placebo-controlled clinical trial requires the development, manufacture, and packaging of the placebo formulation. For oral solid dosage forms such as tablets and capsules, this requires matching the size, shape, and color of the product and at least approximately matching the weight. For liquids, powders, chewable tablets, and orally disintegrating tablets (ODTs), this requires further taste matching. Clinical trial placebos should be manufactured under the same applicable cGMP standards as the active study material.
Matching placebo tablets
Matching a tablet usually means reproducing its size, shape, color, approximate weight, and markings. This requires real formulation development work and starts with procuring the active-containing product and developing the placebo formulation. It is typical to develop formulations based on microcrystalline cellulose (MCC) because they have minimal impact on function and are very inert and suitable for most clinical trials. The bulk of the work goes into ordering tooling of the correct shape, matching debossing characteristics, and matching the coating color, if any.
For a straightforward custom tablet, a practical allowance is about one month for custom tooling and raw materials procurement, followed by another month for non-cGMP formulation development. Upon completion of formulation development, the sponsor typically approves the placebo prototype, and cGMP manufacturing can commence. Depending on the batch size and complexity, the entire process can take three to five months from start to finish.
Matching placebo capsules
With capsules, the shell controls much of the appearance. Matching a standard size and color is much simpler than reproducing a custom tablet.
Complications arise with unusual sizes, custom colors, and printed markings. Capsule suppliers have minimum order quantities and long lead times for these features, which can exceed the needs of a small study.
When both active and placebo are being manufactured for the trial, using the same standard opaque shell for both can simplify the project. Fill weight and capsule handling still need attention: identical shells can feel different if one is substantially heavier or more tightly filled.
Standard capsule procurement can take as little as two weeks, with roughly another month for cGMP manufacturing.
For capsules, just as for tablets, MCC-based formulations are ideal because they flow well, are cheap, and are relatively inert.
Overencapsulation: appearance, rattling, and drug release
Overencapsulation places a commercial tablet or capsule inside a larger opaque capsule. It conceals the original product’s color, shape, and markings without requiring a complete replica.
However, a tablet can rattle inside the outer capsule. A powder-filled placebo might look identical but sound different when shaken. Two practical solutions are backfilling to limit movement or placing a matching placebo tablet inside the same capsule shell.
Overencapsulation also changes how the active product reaches the gastrointestinal environment. The outer capsule must open or dissolve before the tablet can behave as intended, and added filler can affect wetting or drug release.
For clinical programs not governed by an IND, a simple disintegration test in low-pH medium simulating the stomach can assess capsule dissolution and tablet breakup. For IND programs, FDA guidance describes comparative dissolution profiles before and after overencapsulation in media at pH 1.2, 4.5, and 6.8, with additional justification when new excipients are required.
Overencapsulating the active-containing tablet may introduce the need to perform stability studies to establish shelf life as commercially available tablet products usually have shelf life determined specifically without overencapsulation and in specific commercially available bottles.
Check the purchased active lot’s remaining shelf life before setting batch quantities and the supply schedule.
Selecting ingredients and matching liquids or powders
Microcrystalline cellulose, or MCC, is a common starting material for solid oral placebos. Other excipients provide the flow, binding, lubrication, or coating properties needed for manufacturing.
The ingredient list also needs review against the study population and endpoints. Lactose is undesirable when lactose intolerance is a concern. An ingredient intended to imitate a supplement’s taste or texture should not introduce a dietary component that could influence the results.
Liquids and powders require evaluation in the form participants will consume. A powder that resembles the active when dry can differ after mixing because of grittiness, sedimentation, color, or aroma. Liquid matching includes sweetness, bitterness, viscosity, and aftertaste.
For aqueous liquids, preservation and microbial quality need particular attention. A suitable preservative system or other supported microbial-control strategy is part of formulation development.
Release testing: when an HPLC assay is needed
For an FDA IND study, placebo release testing includes demonstrating the absence of the active ingredient. For a typical small-molecule tablet or capsule, this is done using an HPLC assay that can detect the active in the placebo formulation at a defined acceptance limit.
If the sponsor supplies an existing assay method, it needs to be transferred and checked for suitability. Sample preparation and background peaks can differ between the active and placebo formulations.
If no suitable method is available, initial HPLC method development typically takes about two weeks once reference standards and samples are available. Required qualification or validation adds to that schedule. All analytical testing methods must also comply with applicable cGMP requirements and SOPs.
For IND-exempt studies, an absence-of-active assay need not be a requirement. Its inclusion is determined case by case by the sponsor, with input from the study pharmacist or quality team and IRB, consistent with the protocol and applicable quality requirements. IND exemption does not remove the need for appropriate quality controls.
Microbiological and heavy-metals testing are separate considerations, including for supplement studies. The relevant specifications should be established before the batch is manufactured so samples and laboratory work are included in the scope of work and in the release plan.
Multiple manufacturing tranches
A long trial does not necessarily need a batch that lasts for the entire study. If a batch has a supported six-month use period, manufacturing two years of supply upfront creates an obvious mismatch and risks stability and shelf-life-related failures. Fresh manufacturing campaigns can instead supply successive enrollment periods.
Each tranche needs enough usable shelf life for release, shipping, recruitment, and completion of participant dosing. Manufacturing smaller batches spreads spending, although repeated setup and release work can increase the total cost. A suitable stability program can sometimes support larger campaigns and fewer manufacturing runs.
Phased manufacturing can avoid waiting for a completed long-term stability study before starting the trial. It does not remove the need to justify the use period of each batch; stability monitoring can continue during the study where appropriate.
Clinical packaging and the final handoff
Matching active and placebo must extend to the containers, labels, and presentation participants receive.
For powders, premeasured sachets reduce measuring steps and support consistent dosing. For tablets and capsules, bottle counts and dosing instructions need to align with the protocol.
When material is supplied in bulk to a separate clinical packager, the receiving team needs lot identification, quantities, release documentation, dating, and storage instructions. Missing information can delay packaging even when manufacturing is complete.
The choice of placebo formulation, batch size, testing, and packaging should therefore be considered together.
See four practical examples of placebo manufacturing and clinical supply planning.
Vici Health Sciences develops and manufactures nonsterile placebo clinical supplies for pharmaceutical and supplement studies. Contact our industry experts to discuss a specific reference product, study schedule, or supply challenge.
